Anupam Rasayan India Ltd

Anupam Rasayan India Product Launch

Anupam Rasayan commercialised ETFA using flow chemistry, a world-first. This strengthens its specialty chemicals portfolio and global market position.

Anupam Rasayan India Open Offer: ₹829 Cr

Anupam Rasayan announced a ₹829.03 Crore open offer to acquire a 26% stake in Bliss GVS Pharma Limited. The move follows a majority stake acquisition via SPA.

Value

₹829.0 Cr

Execution

Tendering period starts July 16, 2026, and closes July 29, 2026

Anupam Rasayan India Other Announcement

Anupam Rasayan scheduled a plant visit for several institutional investors on June 9, 2026. The visit at Jhagadia GIDC involves analysts from Prabhudas Liladhar and Marcellus.

Anupam Rasayan India Earnings Call: Key Takeaways

Q4FY25 saw 31% QoQ consolidated revenue growth. Full year FY25 consolidated revenue was ₹14,485 Mn, a 4% YoY degrowth, reflecting H1 macro weakness recovered in H2.

Anupam Rasayan India Credit Rating

India Ratings and Research updated Anupam Rasayan's credit rating to 'IND AA-' with Negative Implications. Ratings cover bank loans and NCDs, reflecting current creditworthiness assessments.

Anupam Rasayan India Credit Rating

CRISIL assigned 'Crisil A+' to Anupam Rasayan's ₹160 Crore NCDs and placed ₹1,620 Crore bank facilities on rating watch. This follows the acquisition of Bliss GVS Pharma.

Value

₹1,780 Cr

Anupam Rasayan India Share Pledge

Anupam Rasayan promoter Anand Sureshbhai Desai pledged 31,50,000 shares to secure ₹160 Crore in non-convertible debentures. This transaction increases total promoter encumbrances to 6.13%.

Value

₹160.0 Cr

Anupam Rasayan India Earnings Call: Key Takeaways

Anupam Rasayan delivered record FY26 revenue of ₹2,384cr, up 65% YoY, driven by acquisitions and diversification into Pharma and Fluorination.

Anupam Rasayan India Other Announcement

Anupam Rasayan India Ltd submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no material deviations.

Anupam Rasayan India Debt & Borrowing: ₹160 Cr

Anupam Rasayan allotted ₹160 Crore of secured non-convertible debentures to Aditya Birla Capital. The unlisted 10.25% coupon instruments carry a 13-month tenure for debt repayment.

Value

₹160.0 Cr

Execution

13 months

Anupam Rasayan India Earnings Call: Key Takeaways

Anupam Rasayan delivered record FY26 revenue of ₹2,384cr, driven by aggressive acquisitions (J-Hock, Bliss GVS) and a pivot from agrochemicals to high-margin pharma and polymer segments.

Anupam Rasayan India Acquisition Worth ₹1,370 Cr

Anupam Rasayan will acquire a controlling 43.30% stake in Bliss GVS Pharma for ₹1369.51 Crore. This strategic acquisition integrates pharmaceutical operations and unlocks operational synergies.

Value

₹1,370 Cr

Execution

Expected to be completed within 6 months.

Anupam Rasayan India Dividend

Anupam Rasayan recommended a final dividend of ₹1.5 per equity share for FY 2025-26. This 15% payout rewards shareholders, though the record date remains pending.

Anupam Rasayan India Earnings Call: Key Takeaways

Anupam Rasayan announced the acquisition of Bliss GVS Pharma (43.3-48.2% stake plus open offer) to expand into pharmaceutical formulations and regulated markets like the USA.

Anupam Rasayan India Earnings Call: Key Takeaways

Anupam Rasayan reported record FY26 consolidated revenue of ₹23,836 Mn (up 65% YoY) and PAT of ₹2,222 Mn (up 39% YoY). Strategy focuses on backward integration via Tanfac and US expansion through Jayhawk acquisition.

Anupam Rasayan India Acquisition Worth ₹300 Cr

Anupam Rasayan announced a ₹300 Crore acquisition of a 43.3-48.2% stake in Bliss GVS Pharma Limited. The deal integrates its specialty chemical capabilities with pharmaceutical formulations.

Value

₹300.0 Cr

Anupam Rasayan India Results Update

Anupam Rasayan reported FY26 revenue of ₹2,383.60 Crore, a 65% YoY increase. Performance was driven by landmark sales, strategic expansion, and the Jayhawk acquisition.

Value

₹2,384 Cr

Anupam Rasayan India Board Meeting Outcome

Anupam Rasayan's board approved the re-appointment of its internal and cost auditors for FY 2026-27. The meeting concluded today, ensuring continuity in corporate governance and audit functions.

Execution

Financial Year 2026-27

Anupam Rasayan India Management Change

Mr. Vishal Thakkar resigned as Deputy CFO and Key Managerial Personnel effective May 23, 2026. He departs to explore internal Group opportunities and personal ventures.

Anupam Rasayan India Acquisition Worth ₹2,250 Cr

Anupam Rasayan will acquire up to 74.20% of Bliss GVS Pharma for approximately ₹2250.36 Crore. This strategic acquisition strengthens the company's presence across the pharmaceutical value chain.

Value

₹2,250 Cr

Execution

6 months

Anupam Rasayan India Q4 FY26 Results: Net Profit ₹56 Cr, Down 11.0% YoY

Anupam Rasayan India Ltd reported revenue from operations of ₹635.8 Cr (+27.1% YoY) and net profit of ₹56 Cr (-11.0% YoY) for Q4 FY26.

Key figure

Net profit ₹56 Cr · -11.0% YoY

Anupam Rasayan India Financial Results

Anupam Rasayan reported audited FY2026 financial results and recommended a ₹1.5 dividend per share. The board also approved a 74.20% acquisition of Bliss GVS Pharma.

Value

₹1.50 Cr

Anupam Rasayan India Board Meeting Date

Anupam Rasayan India Limited has scheduled a board meeting for May 23, 2026. The board will consider audited yearly financial results, final dividend, and fund raising.

Anupam Rasayan India Board Meeting Date

Anupam Rasayan India Ltd scheduled a board meeting for May 23, 2026. Directors will consider financial results, a final dividend, and ₹160 Crore NCD issuance.

Value

₹160.0 Cr

Anupam Rasayan India Annual General Meeting

Anupam Rasayan India Limited announced the successful passage of resolutions via postal ballot. Shareholders approved guarantees and security interests for credit facilities involving subsidiary Doriath S.a.r.l.

Anupam Rasayan India Annual General Meeting

Anupam Rasayan India Limited shareholders approved two resolutions via postal ballot with majority. The voting results and scrutinizer's report were formally filed today.